Woodline Partners LP increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 1,919.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 189,126 shares of the company’s stock after purchasing an additional 179,759 shares during the quarter. Woodline Partners LP owned 0.24% of CRISPR Therapeutics worth $11,871,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. National Bank of Canada FI increased its position in shares of CRISPR Therapeutics by 41.1% during the 1st quarter. National Bank of Canada FI now owns 1,634 shares of the company’s stock valued at $101,000 after purchasing an additional 476 shares during the last quarter. Virginia Retirement Systems ET AL increased its position in shares of CRISPR Therapeutics by 6.4% during the 1st quarter. Virginia Retirement Systems ET AL now owns 18,200 shares of the company’s stock valued at $1,142,000 after purchasing an additional 1,100 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $289,982,000. Qube Research & Technologies Ltd increased its position in shares of CRISPR Therapeutics by 189.6% during the 1st quarter. Qube Research & Technologies Ltd now owns 81,592 shares of the company’s stock valued at $5,122,000 after purchasing an additional 53,414 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in shares of CRISPR Therapeutics by 49.4% during the 1st quarter. HighTower Advisors LLC now owns 49,883 shares of the company’s stock valued at $3,129,000 after purchasing an additional 16,496 shares during the last quarter. Institutional investors own 70.56% of the company’s stock.
CRISPR Therapeutics Price Performance
Shares of NASDAQ CRSP opened at $66.96 on Monday. The stock has a market capitalization of $5.22 billion, a P/E ratio of -8.14 and a beta of 1.97. CRISPR Therapeutics AG has a 1-year low of $42.51 and a 1-year high of $124.79. The business has a fifty day moving average price of $73.83 and a 200 day moving average price of $64.81.
Insider Buying and Selling
In related news, CEO Samarth Kulkarni sold 25,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total transaction of $1,897,750.00. Following the completion of the sale, the chief executive officer now directly owns 290,279 shares in the company, valued at approximately $22,035,078.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 75,000 shares of company stock worth $5,108,500 in the last three months. 5.30% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several equities analysts have commented on the company. Stifel Nicolaus upped their price objective on CRISPR Therapeutics from $55.00 to $69.00 in a research report on Tuesday, August 9th. Barclays downgraded CRISPR Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $99.00 to $88.00 in a research report on Tuesday, August 9th. Oppenheimer cut their price objective on CRISPR Therapeutics from $150.00 to $122.00 and set an “outperform” rating on the stock in a research report on Thursday, June 23rd. The Goldman Sachs Group cut their price objective on CRISPR Therapeutics from $52.00 to $46.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 24th. Finally, Citigroup upped their price objective on CRISPR Therapeutics from $53.00 to $83.00 and gave the company a “neutral” rating in a research report on Tuesday, August 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $112.33.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here’s Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.